NCT07711847RecruitingNot Applicable
Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery
HeroSupport SA1 site in 1 country30 target enrollmentStarted: July 1, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Feasibility outcome: Time (days) between surface scan data received by HeroSupport and arrival of the VENUS SHELL™ at the clinical site
Study Overview
Brief Summary
The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort during prone radiotherapy (radiotherapy given while the patient lies on her stomach).
The main goals of the study are:
- To confirm that using the VENUS SHELL™ is safe and effective
- To assess whether the VENUS SHELL™ helps deliver accurate radiation treatment in a faster and more comfortable way
Participants will:
- Attend a study visit before radiotherapy to have a breast surface scan (no radiation) and enable the production of their personalized VENUS SHELL™
- Use their VENUS SHELL™ during radiotherapy planning and treatment
- Be asked to complete questionnaires about their comfort
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent according to ICH/GCP regulations before registration and prior to any study-specific procedures
- •Upfront breast conservative surgery
- •Radiotherapy planned within 12 weeks after surgery
- •ECOG/WHO performance status ≤2
- •Age ≥40 year
- •For invasive breast cancer only:
- •Staging pT1-T2, N0M0 (Tumor size ≤3 cm)
- •If no sentinel lymph node biopsy performed, patient must be clinically N0
- •Negative margins (no tumor on ink)
- •For ductal carcinoma in situ only:
- •Staging pTis (tumor size ≤3 cm)
- •Negative margins (≥2 mm)
Exclusion Criteria
- •Patient of male sex
- •Inability to obtain informed consent or adhere to the CIP
- •Breast skin damage that could prevent VENUS SHELL™ usage according to protocol timeline (e.g. presence of any skin or soft tissue wound that failed to show evidence of progression towards healing, clinical signs of active infection at or immediately adjacent to the intended intervention site, etc.)
- •Known germline BRCA1/2 mutation
- •Unable to lay prone
- •Unable to undergo imaging by CT scan
- •Documented hypersensitivity or allergy to medical plasters, acrylonitrile butadiene styrene
- •Any serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may affect patient compliance or place the patient at high risk within the study.
- •Pregnancy or breast feeding
- •Claustrophobia
- •Patient with a body weight exceeding 120 kg
- •Patient with pendulous breasts that come into contact with the CT table, preventing adequate space for shell usage
- •Presence of any cardiac implantable electronic device (CIED), including but not limited to a pacemaker, implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT) device, or other electronically active implant.
Outcomes
Primary Outcomes
Feasibility outcome: Time (days) between surface scan data received by HeroSupport and arrival of the VENUS SHELL™ at the clinical site
Time Frame: Treatment set-up (up to 21 days)
Performance outcomes: radiotherapy delivered within 15 minutes timeslot and patient positioning accuracy within 2 mm
Time Frame: Study treatment (10 days)
Radiotherapy time includes patient positioning and treatment. Patient positioning accuracy is measured though displacement via Tattoos and Image-Guided Radiation Therapy imaging
Safety outcome: number of medical device-related Adverse Events as assessed by CTCAE v5.0
Time Frame: Through study completion (an average of 3 months)
Secondary Outcomes
- Patients' comfort (questionnaires)(Treatment set-up (up to 21 days) and study treatment (10 days))
- Evaluate ease of use and overall satisfaction of using the VENUS SHELL (questionnaires)(Study treatment (10 days))
- In-vivo dosimetry measured with thermoluminescent dosimeters (TLDs)(Radiotherapy treatment first session, up to last session (10 days))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Study Comparing Two Types of Radiation Therapy for Early-Stage Breast Cancer: Partial vs. Whole Breast IrradiationCTRI/2025/01/078980Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh40
Recruiting
Not Applicable
BRAVE-HEART: Breast Cancer Radiotherapy Using Active Breathing Coordinator to aVoid Exposure of HEARTBreast CancerNCT07299812Fondazione IRCCS Policlinico San Matteo di Pavia400
Recruiting
Not Applicable
Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm StudyLung CancerNCT07554677Queen's University, Belfast30
Active, not recruiting
Phase 3
A clinical trial to study the prevention of pain syndrome caused by chemotherapy paclitaxel in cancer patients by oral drug duloxetine compared to placebo.CTRI/2024/10/075636Indian Council of Medical Resaerch204
Not yet recruiting
Not Applicable
Comparing the Dosimetric Effects of Sequential and Simultaneously-Integrated Boost in Breast Cancer Patients After Breast-Conserving SurgeryCTRI/2024/12/077538Dr. Rahul Thakur40